FIALA, Ondrej, Pavel OSTASOV, Petr HOSEK, Ondrej SOREJS, Vaclav LISKA, Tomas BUCHLER, Alexandr POPRACH, Radek KUCERA, Ondrej TOPOLCAN, Jan SUSTR, Monika SEDIVCOVA a Jindrich FINEK. The Predictive Role of Primary Tumour Sidedness in Metastatic Colorectal Cancer Treated With Targeted Agents. Anticancer Research. Athens: International Institute of Anticancer Research, 2019, roč. 39, č. 10, s. 5645-5652. ISSN 0250-7005. Dostupné z: https://dx.doi.org/10.21873/anticanres.13761. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1604881, author = {Fiala, Ondrej and Ostasov, Pavel and Hosek, Petr and Sorejs, Ondrej and Liska, Vaclav and Buchler, Tomas and Poprach, Alexandr and Kucera, Radek and Topolcan, Ondrej and Sustr, Jan and Sedivcova, Monika and Finek, Jindrich}, article_location = {Athens}, article_number = {10}, doi = {http://dx.doi.org/10.21873/anticanres.13761}, keywords = {Primary tumour sidedness; colorectal cancer; cetuximab; panitumumab; bevacizumab}, language = {eng}, issn = {0250-7005}, journal = {Anticancer Research}, title = {The Predictive Role of Primary Tumour Sidedness in Metastatic Colorectal Cancer Treated With Targeted Agents}, url = {http://dx.doi.org/10.21873/anticanres.13761}, volume = {39}, year = {2019} }
TY - JOUR ID - 1604881 AU - Fiala, Ondrej - Ostasov, Pavel - Hosek, Petr - Sorejs, Ondrej - Liska, Vaclav - Buchler, Tomas - Poprach, Alexandr - Kucera, Radek - Topolcan, Ondrej - Sustr, Jan - Sedivcova, Monika - Finek, Jindrich PY - 2019 TI - The Predictive Role of Primary Tumour Sidedness in Metastatic Colorectal Cancer Treated With Targeted Agents JF - Anticancer Research VL - 39 IS - 10 SP - 5645-5652 EP - 5645-5652 PB - International Institute of Anticancer Research SN - 02507005 KW - Primary tumour sidedness KW - colorectal cancer KW - cetuximab KW - panitumumab KW - bevacizumab UR - http://dx.doi.org/10.21873/anticanres.13761 L2 - http://dx.doi.org/10.21873/anticanres.13761 N2 - Background/Aim: The aim of our study was to assess the predictive role of primary tumour sidedness (PTS) in patients with metastatic colorectal cancer (mCRC) harbouring wild-type RAS and treated with targeted agents. Patients and Methods: The cohort included 178 patients treated with first-line chemotherapy plus cetuximab, panitumumab or bevacizumab. Results: We observed longer progression-free survival (PFS) and overall survival (OS) in patients with left-sided (L-CRC) compared to right-sided tumours (R-CRC) treated with anti-EGFR mAbs (p=0.0033 and p=0.0037), while there was no difference in patients treated with bevacizumab (p=0.076 and p=0.56). Finally, we observed longer PFS and OS in patients with L-CRC treated with anti-EGFR mAbs and those with R-CRC treated with bevacizumab compared to the reverse combination (p=0.0002 and p=0.011). Conclusion: PTS is a predictive factor for anti-EGFR mAbs, not for bevacizumab. Superior survival was observed when anti-EGFR mAbs were used for L-CRC and bevacizumab for R-CRC. ER -
FIALA, Ondrej, Pavel OSTASOV, Petr HOSEK, Ondrej SOREJS, Vaclav LISKA, Tomas BUCHLER, Alexandr POPRACH, Radek KUCERA, Ondrej TOPOLCAN, Jan SUSTR, Monika SEDIVCOVA a Jindrich FINEK. The Predictive Role of Primary Tumour Sidedness in Metastatic Colorectal Cancer Treated With Targeted Agents. \textit{Anticancer Research}. Athens: International Institute of Anticancer Research, 2019, roč.~39, č.~10, s.~5645-5652. ISSN~0250-7005. Dostupné z: https://dx.doi.org/10.21873/anticanres.13761.
|